Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
[13] Treatment was given for 104 weeks (2 years), and the occurrence of cardiovascular events, including heart attacks, strokes, and hospitalization due to unstable angina (near heart attack) were recorded and compared in the two groups of participants
The approval significantly expanded the commercial opportunity for GLP-1-based obesity therapies and intensified competition with Wegovy in the rapidly growing anti-obesity drug market In March 2024, Novo Nordisk secured U.S
17,18 In a post-hoc analysis of the SUSTAIN-6 study, the additional risk factors of speed of hemoglobin A1c reduction with treatment, poor baseline glycemic control and insulin use at the initiation of GLP-1/GIP agonist treatment were reported ( Table 2 )
75 KosteljanetzM.IngstrupH
Plan for the Transition and Manage Expectations Gradual tapering Tapering refers to slowly decreasing your dose this is typically recommended over stopping GLP-1 medication abruptly
